Opus Genetics Announces One-Month Clinical Data from Pediatric Patient in Phase 1/2 Trial of OPGx-LCA5 Gene Therapy in Inherited Retinal Diseases

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics to Present at the J.P. Morgan 2026 Healthcare Conference
Opus Genetics Announces Positive Recommendation from Independent Data Monitoring Committee for Phase 1/2 Trial in Best Disease
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Opus Genetics to Participate in Upcoming Investment Conferences
Opus Genetics Announces Dosing of First Participant in OPGx-BEST1 Phase 1/2 Gene Therapy Clinical Trial for Best Disease
Opus Genetics Announces Financial Results for Third Quarter 2025 and Provides Corporate Update
Opus Genetics Announces $23 Million Registered Direct Offering

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.